Zacks Research Upgrades Prestige Consumer Healthcare (NYSE:PBH) to Hold

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Several other brokerages have also commented on PBH. Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Finally, Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $70.75.

Prestige Consumer Healthcare Trading Up 1.1%

Shares of NYSE:PBH opened at $53.57 on Monday. The business’s 50-day moving average is $49.11 and its 200 day moving average is $55.82. Prestige Consumer Healthcare has a 1 year low of $42.62 and a 1 year high of $71.07. The firm has a market capitalization of $2.54 billion, a P/E ratio of 15.00, a P/E/G ratio of 1.66 and a beta of 0.34. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The company had revenue of $265.71 million during the quarter, compared to analysts’ expectations of $253.02 million. During the same period last year, the business posted $0.90 earnings per share. The firm’s revenue was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, research analysts predict that Prestige Consumer Healthcare will post 4.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PBH. UMB Bank n.a. boosted its position in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after buying an additional 219 shares during the last quarter. Bayforest Capital Ltd acquired a new position in Prestige Consumer Healthcare in the 4th quarter worth approximately $29,000. Versant Capital Management Inc raised its position in Prestige Consumer Healthcare by 47.9% during the 2nd quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock worth $34,000 after buying an additional 235 shares during the last quarter. Torren Management LLC purchased a new position in Prestige Consumer Healthcare during the 4th quarter worth approximately $35,000. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Prestige Consumer Healthcare by 69.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after acquiring an additional 236 shares during the period. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).